Evaluating chidamide for maintaining treatment in PTCL patients
A Retrospective (Non-interventional) Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide.
This study is testing if chidamide can help people with peripheral T-cell lymphoma stay in remission after their initial treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05967949 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the efficacy and safety of chidamide as a first-line maintenance therapy for patients diagnosed with peripheral T-cell lymphoma (PTCL). It involves a retrospective analysis of patient data collected from those who received chidamide after initial treatment. The study will analyze various factors including patient demographics, previous treatment regimens, and results from auxiliary examinations such as blood tests and imaging studies to determine the outcomes associated with chidamide therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with PTCL and have received chidamide as maintenance therapy.
Not a fit: Patients with other types of lymphomas or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of chidamide as a maintenance treatment for PTCL, potentially improving patient outcomes.
How similar studies have performed: While this study focuses on a specific retrospective analysis, similar approaches in evaluating maintenance therapies for lymphomas have shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment. Exclusion Criteria: * (1) Patients with other types of lymphomas; (2) Pregnant women.
Where this trial is running
Nanjing, Jiangsu
- Hematological Department, People's Hospital of Jiangsu Province — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: wei xu
- Email: xuwei10000@hotmail.com
- Phone: +862568302182
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.